High-Dose Naltrexone Treatment and Gender in Alcohol Dependence

2016 ◽  
Vol 39 (4) ◽  
pp. 165-168 ◽  
Author(s):  
Gihyun Yoon ◽  
Suck Won Kim ◽  
Ismene Leonida Petrakis ◽  
Joseph Westermeyer
2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S967-S967
Author(s):  
Misti Paudel ◽  
Salah Mahmud ◽  
Ami R Buikema ◽  
Stephanie Korrer ◽  
Van Voorhis Damon ◽  
...  

Abstract Background High dose (HD) influenza vaccine has been shown to be more efficacious than standard dose (SD) vaccine in multiple randomized trials. HD is currently the most commonly used vaccine in US seniors (≥65 years of age). In this study, we evaluated the real-world relative vaccine effectiveness (rVE) of HD vs SD over 3 influenza seasons. Methods This study includes a cohort of Medicare fee-for-service enrollees during influenza seasons 2011–2012 to 2013–2014 who received either HD or SD at a pharmacy or an outpatient clinic. HD recipients were matched 1:1 to SD recipients based on location, date of vaccination, age, and gender. Fine-Gray subdistribution hazard models with competing risk of death were used to adjust for residual confounding. The study outcome of probable influenza was defined as any inpatient stay with an influenza diagnosis on the claim, or an outpatient medical encounter with a rapid influenza test/culture followed by an antiviral prescription. Analyses were stratified based on vaccination location (clinic vs pharmacy) as it is expected that physicians carrying both vaccines may prioritize HD to frailer patients, while pharmacists may not exercise clinical judgment. Results Over the influenza seasons 2011–2012, 2012/–2013, and 2013–2014, 1.6–2.2 million seniors were immunized at a pharmacy; and 3.3–3.5 million at a clinic. After matching, there were 535,598; 1,017,552; and 1,548,164 in the pharmacy cohort, and 821,662; 1,151,080; and 1,559,488 in the clinic cohort, across study years. The rVE over 2011/12, 2012/13, and 2013/14 during peak influenza circulation was 21.8% (95% CI: −5.9%, 42.3%), 14.8% (9.3%,19.9%), and 16.9% (9.2%, 23.9%), respectively, in the pharmacy cohort; and 16.5% (−5.9%, 34.2%), 15.1% (10.9%, 19.1%), 10.0% (2.9%, 16.6%), respectively, in the clinic cohort. Conclusion HD was consistently associated with better protection against probable influenza events requiring outpatient or inpatient care. The slightly lower treatment effects observed in the outpatient clinic cohort could be a result of confounding by indication due to physicians triaging HD to frailer patients. Disclosures All authors: No reported disclosures.


2002 ◽  
Vol 17 (1) ◽  
pp. 1-8 ◽  
Author(s):  
A.M. Möller-Leimkühler ◽  
R. Schwarz ◽  
W. Burtscheidt ◽  
W. Gaebel

SummaryObjectiveThe overall increase of female alcoholism is supposed to be associated with the change of the traditional female role, and it is especially seen as a consequence of role convergence or gender-role conflicts. The aim of the present pilot study is to explore whether the approach of gender-role orientation would be empirically useful in contributing to these hypotheses.MethodOne hundred twelve patients with alcohol dependence meeting DSM-III-R criteria were explored after detoxification; gender-role orientation was measured by a German version of the ‘Extended Personal Attributes Questionnaire’, categorising gender-role orientation into four subgroups: masculine, feminine, androgynous, and undifferentiated.ResultsIn comparison with a population-based sample, there are significant differences in the distribution of the four subgroups of gender-role orientation, showing a predominance of the undifferentiated self-concept in the alcoholic sample (49%). Alcoholic females describe themselves as rather undifferentiated, and rather feminine than masculine. Low masculinity and low femininity, as well as high femininity, correlate positively with distress, depressiveness, social anxiety, insecurity and concomitant personality disorders.ConclusionOur data do not support the convergence hypothesis related to gender-role orientation, but support the traditional feminine self-concept as an unspecific risk factor for vulnerability. The question whether an undifferentiated self-concept could be a specific risk factor for alcoholism is discussed.


2013 ◽  
Vol 48 (3) ◽  
pp. 200-210 ◽  
Author(s):  
Karen G. Chartier ◽  
Michie N. Hesselbrock ◽  
Victor M. Hesselbrock

2018 ◽  
Vol 28 (7) ◽  
pp. 795-806 ◽  
Author(s):  
Mimi Pierce ◽  
Arjen Sutterland ◽  
Esther M. Beraha ◽  
Kirsten Morley ◽  
Wim van den Brink

1987 ◽  
Vol 15 (2) ◽  
pp. 133-144 ◽  
Author(s):  
William H. George ◽  
Mary P. McAfee

Two questionnaire studies evaluated the effects of gender and drinking experience on dose-related alcohol expectancies. In Study 1, the Southwick et al. (1981) expectancy measure was administered to 173 students and no gender differences were found. Consistent with earlier work, increased drinking experience was associated with expectation of more stimulation and pleasure from a moderate alcohol dose. A moderate dose was associated with expectation of more stimulation, more pleasure, and less impairment than a high dose. In Study 2 (n = 174). the instrument was modified to assess alcohol expectancies about a male or female target person. Expectancies about alcohol's effect on the target were determined by both gender of subject and gender of target. Female subjects expected alcohol to produce more stimulation and pleasure for the target person than male subjects expected. The female target was viewed by all subjects as experiencing less stimulation. Male and female subjects disagreed in their perceptions of how much pleasure the female target derives from drinking. As with self expectancies, subjects perceived that alcohol has biphasic effects on others. Implications for social drinking interactions are discussed.


2014 ◽  
Vol 2014 ◽  
pp. 1-3 ◽  
Author(s):  
Beth A. Taylor ◽  
Gregory Panza ◽  
Linda S. Pescatello ◽  
Stuart Chipkin ◽  
Daniel Gipe ◽  
...  

The purpose of the present report was to examine whether proprotein convertase subtilisin/kexin type 9 (PCSK9) levels differ in individuals who do not exhibit expected reductions in low density lipoprotein cholesterol (LDL-C) with statin therapy. Eighteen nonresponder subjects treated with 80 mg atorvastatin treatment for 6 months without substantial reductions in LDL-C (ΔLDL-C: 2.6 ± 11.4%) were compared to age- and gender-matched atorvastatin responders (ΔLDL-C: 50.7 ± 8.5%) and placebo-treated subjects (ΔLDL-C: 9.9 ± 21.5%). Free PCSK9 was marginally higher in nonresponders at baseline(P=0.07)and significantly higher in atorvastatin responders after 6 months of treatment(P=0.04). The change in free PCSK9 over 6 months with statin treatment was higher(P<0.01)in atorvastatin responders (134.2 ± 131.5 ng/mL post- versus prestudy) than in either the nonresponders (39.9 ± 87.8 ng/mL) or placebo subjects (27.8 ± 97.6 ng/mL). Drug compliance was not lower in the nonresponders as assessed by pill counts and poststudy plasma atorvastatin levels. Serum PCSK9 levels, both at baseline and in response to statin therapy, may differentiate individuals who do versus those who do not respond to statin treatment.


Sign in / Sign up

Export Citation Format

Share Document